X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: Besides the US.... - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Mar 20, 2007

    Pharma: Besides the US....

    While the US generics market continues to be a major focus area for most of the major Indian pharma companies, many of them are looking to de-risk their business model by increasing focus on the semi regulated markets of Asia, Russia, CIS, Central Eastern Europe and Africa. This is largely due to the fact that while the US generics market continues to be the largest in the world, increasing level of competition and brutal price erosion has led Indian pharma companies to focus on other markets to sustain their overall revenue and profitability growth.

    Advantages of geographical expansion...

    Higher barriers to entry:Having a widespread geographical reach is characterised by high entry barriers. This is because different markets have different regulations, which involves a deep understanding of the same if pharma companies want to increase their reach across markets. As per our interaction with a leading domestic pharma company, it is not easy to set up a marketing and distribution network in the country, as this again involves higher investments and good relationships with doctors and distributors. To put things into perspective, in the US and UK, where generics are not branded, the marketing efforts are largely towards the distribution chain, which plays a dominant role in the dispensing of generic medicines. However, in semi-regulated markets where generics are branded, marketing efforts are largely targeted towards doctors, who play a significant role in prescribing medicines.

    De-risking revenues:The importance of geographical presence is also highlighted by the fact that difficult conditions in one market can be offset by a healthy performance in some other market. For instance, in 2006, Ranbaxy's performance in the Western Europe (namely the UK, Germany and France) was largely subdued due to various healthcare reforms undertaken by the governments in these countries. Despite this, a stronger performance in the US, India and the Rest of the World markets enabled the company to withstand these pressures.

    Some concerns...

    Regulatory pressures:As mentioned earlier, different countries have different set of regulations, which could impact a company's performance going forward. Case in point is the new German drug law enacted by the German Government, which states that the price differential between the branded drug and the generic drug has to be a minimum of 30%. Considering that Germany has been a lucrative market for generics due to higher price realisations, this has been a negative for generic companies competing in the higher end of the market. Companies such as Betapharm (acquired by Dr.Reddy's) have undertaken aggressive price cuts in response to the law. Similarly, new healthcare reforms have been enacted in France and Brazil as well, which has affected the performance of Indian companies operating in these regions. While the effect of these policies will even out in the long term, their impact on generics in the medium term is likely to be significant.

    Markets on the radar...

    For domestic pharma companies, given the highly competitive nature of the US generics market and the pressure on margins, these companies are laying increased emphasis on the semi-regulated markets of Russia, CIS, Central Eastern Europe and Africa. This is because these markets are branded (i.e. companies can brand the generic medicines) resulting in higher margins and profitability from these regions. Also, the pharmaceutical markets of these countries are currently growing at a much faster pace than the US and European markets and thus will play a significant role in augmenting the overall performance of domestic companies in the long term.

    To sum up...

    Presence across geographies has been gaining momentum across global generic companies. To put things into perspective, Teva (Israel), the largest generics company in the world, which derived nearly 90% of revenues from the US and UK, acquired Ivax for increasing its presence in other markets amongst other reasons. Thus, pre-Ivax, revenues from the Rest of the World (ROW) markets, which accounted for 11% of Teva's total revenues, now account for 16% of revenues post the Ivax acquisition. Given the high barriers to entry, at the end of the day those pharma companies, which have a wider geographical reach, will have the upper edge over their peers in the longer term.

     

     

    Equitymaster requests your view! Post a comment on "Pharma: Besides the US....". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE HEALTHCARE


    Aug 18, 2017 (Close)

    S&P BSE HEALTHCARE 5-YR ANALYSIS

    COMPARE COMPANY

    MARKET STATS